Compounds > rabeprazole-thioether
Page last updated: 2024-11-12

rabeprazole-thioether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rabeprazole-thioether: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9949996
CHEMBL ID51538
SCHEMBL ID1306777
MeSH IDM0513935

Synonyms (65)

Synonym
117977-21-6
rabeprazole sulfide
CHEMBL51538
2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfanyl]-1h-benzimidazole;2-[[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl ]methyl]thio]-1h-benzimidazole
A803859
rabeprazole-thioether
2-{[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methylthio}-1h-benzimidazole
SCHEMBL1306777
2-{[4-(3-methoxypropoxy)-3-methyl pyridine-2-yl]methylthio}-1h-benzimidazole
2-[[[4-(3-methoxy propoxy)-3-methyl pyridine-2-yl]methyl ] thio]-1h-benzimidazole
FT-0642883
2-[[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl ]methyl]thio]-1h-benzimidazole
AKOS015852518
c18h21n3o2s
2-[[[4-(3-methoxy propoxy)-3-methyl pyridine-2-yl ]methyl ] thio]-1h-benzimidazole
R0098
2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylthio]benzimidazole
2-[[[4-(3-methoxy-propoxy)-3-methyl-2-pyridinyl]methyl]thio]-1h-benzimidazole
BSXAHDOWMOSVAP-UHFFFAOYSA-N
2-[{4-(3-methoxypropoxy)-3-methylpyridine-2-yl}methylthio]-1h-benzimidazole
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylthio}-1h-benzimidazole
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]thio]-1h-benzimidazole
2-[{4-(3-methoxypropoxy)-3-methylpyridine-2-yl}-methylthio]-1h-benzimidazole
2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylthio]-1h-benzimidazole
2-[[[3-methyl-4-(3-methoxypropoxy)-2-pyridinyl]methyl]thio]-1h-benzimidazol
2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl thio]-1h-benzimidazole
2-{4-(3-methoxypropoxy)-3-methylpyridine-2-yl}methylthio-1h-benzimidazole
2-[{4-(3-methoxypropoxy)-3-methylpyridine-2-yl}methylthio]-1h benzimidazole
mfcd08063845
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]thio]benzimidazole
SY030473
2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfanyl]-1h-benzimidazole
2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)thio)-1h-benzo[d]imidazole
W-200910
rabeprazole impurity e
rabeprazole sulfide [usp impurity]
2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfanyl)-1h-benzimidazole
rabeprazole thioether
rabeprazole sodium impurity b [ep impurity]
304S7E320P ,
1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)thio)-
rabeprazole impurity e [usp-mc]
unii-304s7e320p
AC-22627
AC-22626
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfanyl)-1h-benzimidazole
DTXSID20433250
2-{[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methylthio}-1h -benzimidazole
2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)thio)-1h-benzimidazole
2-{[4(3-methoxypropoxy)-3-methyl pyridine-2-yl]methylthio}-1h-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfanyl]-1h-benzimidazole
CS-W003467
2-[[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methyl]thio]-1h-benzimidazole
2-[[[4-(3-methoxy propoxy)-3-methyl pyridine-2-yl]methyl] thio] -1h-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methylthio]-1h-benzimidazole
1185084-49-4
DS-14347
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylthio)-1h-benzo[d]imidazole
2-((4(3-methoxypropoxy)-3-methylpyridine-2-yl)methylthio)-1h-benzimidazole
BCP12237
Q27255911
S5885
HY-W003467
2-{[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]-methythio}-1h-benzimidazole
rabeprazole-d3sulfide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Full plasma pharmacokinetic (PK) profiles of rabeprazole and its thioether metabolite were collected; concentrations were estimated via LC-MS/MS."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38

Bioavailability

ExcerptReferenceRelevance
" A greater understanding of metabolic stability and its modulation by pharmaceutical excipients would be useful for optimizing the bioavailability of rabeprazole at the early formulation stages."( In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients.
Kim, A; Lee, BJ; Park, MJ; Ren, S, 2008)		0.35
"The primary objective of this study-conducted on the sponsor's initiative-was to compare the bioavailability of rabeprazole granules when mixed with various dosing vehicles (small amount of soft food or infant formula) with that of a rabeprazole suspension with inactive vehicle granules (reference), to determine which dosing vehicle can be used to deliver rabeprazole in children."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38
"In these healthy adult subjects, the bioavailability of rabeprazole granules was comparable between all of the dosing vehicles tested, and rabeprazole was well tolerated."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38

Dosage Studied

ExcerptRelevanceReference
"The primary objective of this study-conducted on the sponsor's initiative-was to compare the bioavailability of rabeprazole granules when mixed with various dosing vehicles (small amount of soft food or infant formula) with that of a rabeprazole suspension with inactive vehicle granules (reference), to determine which dosing vehicle can be used to deliver rabeprazole in children."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38
" In a randomized sequence, fasting subjects received a single dose of 10-mg rabeprazole granules per treatment period, mixed with small amounts of 1 of 5 dosing vehicles (a strawberry-flavored suspension of rabeprazole granules with inactive vehicle granules reconstituted with water, yogurt [1 tablespoon], applesauce [1 tablespoon], or infant formula [5 mL], or a suspension of rabeprazole granules with inactive vehicle tablet reconstituted with water)."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38
" Rabeprazole and rabeprazole thioether plasma PK properties were comparable between all of the dosing vehicles tested."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38
"In these healthy adult subjects, the bioavailability of rabeprazole granules was comparable between all of the dosing vehicles tested, and rabeprazole was well tolerated."( Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Solanki, B; Thyssen, A; Treem, W, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID87803Antibacterial activity against Helicobacter pylori strain.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Structure-activity relationship of 2-[[(2-pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy.
AID26759Lipophilicity (log Ko)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Structure-activity relationship of 2-[[(2-pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		11.1762benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		1.9910penicillin allergen;
penicillin		antibacterial drug
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		3.4111macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
omeprazole sulfide
omeprazole sulfide: omeprazole metabolite; structure given in first source		1.9910benzimidazoles
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		3.4111(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Helicobacter
[description not available]		01.9910
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		01.9910
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.1110